HIV Prevention Drugs - Prescribing, Dispensing, and Insurance Coverage

HB 1114 allows pharmacists to prescribe and dispense HIV prevention drugs (PrEP) to patients under specific guidelines, expanding access beyond traditional doctor visits. It requires Maryland's Medicaid program (Medical Assistance Program) to cover FDA-approved HIV prevention drugs, including PrEP and PEP (post-exposure prophylaxis), starting January 1, 2027. The bill also prohibits insurers and managed care organizations from requiring prior authorization, step therapy, or cost-sharing for these medications. This directly affects pharmacists, Medicaid recipients, and health insurers by removing financial and administrative barriers to HIV prevention care. The policy aligns with CDC guidelines for PrEP and PEP use, ensuring coverage for medically appropriate HIV prevention drugs.